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Abstract
Background: Chronic obstructive pulmonary disease (COPD) impairs quality of life and leads to premature
mortality. COPD sufferers experience progressive deterioration of lung function and decreased ability to undertake
day-to-day activities. Ginseng has been used for thousands of years in Chinese medicine for respiratory symptoms.
Several controlled clinical trials using ginseng for COPD have shown promising clinical effect, however these
studies were generally small and with some potential bias, prompting the need for rigorously designed studies.
Aim: The objective of this study is to evaluate the therapeutic value and safety profile of a standardised root
extract of Panax ginseng C.A Meyer (ginseng) for symptomatic relief, with a focus on quality of life (QoL)
improvements in individuals with moderate (Stage II) COPD FEV1/FVC < 0.7 and FEV1 50% - 80% predicted.
Methods: This paper describes the design of a randomised, multi-centre, double-blind, placebo controlled, two-
armed parallel clinical trial. Two trial sites in Melbourne Australia will proportionately randomise a total of 168
participants to receive either ginseng capsule (100 mg) or matching placebo twice daily for 24 weeks. The primary
outcomes will be based on three validated QoL questionnaires, St Georges Respiratory Questionnaire (SGRQ), Short
Form Health Survey (SF-36) and the COPD Assessment Test (CAT). Secondary outcomes are based on lung function
testing, relief medication usage and exacerbation frequency and severity. Safety endpoints include blood tests and
adverse event reporting. Intention-to-treat will be applied to all data analyses.
Discussion: Findings from this study may lead to new therapeutic development for chronic respiratory diseases,
particularly COPD. This protocol may also guide other investigators to develop quality herbal medicine clinical trials
in the future.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12610000768099
Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and mortality worldwide [1].
Current estimates of its prevalence in the adult popula-
tion (≥ 40 years old) are reported at approximately 10%
[2] with global leading cause of death projections rank-
ing COPD 3rd by 2030 [3]. COPD is widely accepted as
a preventable disease, but due to continued inhalation
of noxious substances, particularly cigarette smoke,
COPD is expected to be a major burden for individuals
and health care providers for the foreseeable future. Due
to limited reversibility and progression, mild symptoms
can develop in severity particularly if smoking persists
and symptoms are poorly managed. Even after smoking
cessation individuals can experience progressive airflow
limitation and increased shortness of breath, chronic
cough, sputum production and impaired quality of life
(QoL). Therefore, early diagnosis and treatment of
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COPD can reduce the likelihood of symptom deteriora-
tion, disease progression and improve overall outcomes
[4].
Severity classification of COPD has been defined by the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) into four stages, mild (Stage I), moderate (Stage
II), severe (Stage III) and very severe (Stage IV). Classifi-
cation is determined by spirometric measurements using
post-bronchodilator forced expiratory volume in 1 sec
(FEV1) and its ratio to forced vital capacity (FVC) [5]. All
stages of COPD, mild to very severe are associated with
impaired QoL [6].
Currently there is no cure for COPD. Due to its irrever-
sible nature, conventional treatments primarily intend to
control and alleviate symptoms, and to prevent complica-
tions. Commonly used treatments include bronchodilators,
corticosteroids (for severe cases), and antibiotics (for
exacerbations). However, these treatments produce only
modest increases in lung function and are associated with
a range of adverse effects [7,8]. With improved under-
standing of the cellular and molecular mechanisms
involved in COPD, some novel approaches to treatment
are currently under investigation, including pro-inflamma-
tory mediator antagonists, protease inhibitors and phos-
phodiesterase 4 (PDE4) inhibitors [8]. Yet, for the drugs so
far developed, clinical usefulness has been limited by
adverse effects [8,9].
Current internationally accepted guidelines recom-
mend symptomatic treatment for COPD with short or
long-acting bronchodilators [5]. The addition of regular
treatment with inhaled steroids to bronchodilators is
only appropriate for more severe symptomatic patients
FEV1 < 50% predicted (GOLD stages III and IV) and
with repeated exacerbations [1]. Although commonly
used in mild to moderate COPD patients (GOLD stages
I and II) in the community, inhaled steroids are not
recommended for this group of patients [5]. It is in this
group of symptomatic moderate patients (GOLD stage
II), who are often exposed to inhaled steroids without
any evidence of benefit, but are at risk of long-term
side-effects such as cataracts and osteoporosis, that we
seek an alternative and safe treatment approach in this
important clinical study.
There is growing interest and use of complementary
and alternative medicines for the management of
COPD. A recent study in Australia suggested that nearly
one in six (17.3%) individuals with COPD had used
some form of herbal preparation [10]. Despite increasing
use by COPD sufferers, there is inadequate evidence to
support routine use of herbal therapies.
Panax ginseng C.A Meyer (ginseng) root is an impor-
tant Chinese herbal medicine in use for thousands of
years. Recently pharmacologically active constituents
have been identified, most notably ginsenosides [11].
Potentially relevant activities of these constituents for
COPD include, inhibition of pro-inflammatory media-
tors and cytokines [12], reduction of oxidative stress
[13], anti-protease properties [14] and elevation of
cAMP [15]. As well as having pharmacologically active
constituents, ginseng has an excellent safety profile and
is well tolerated by patients [16].
A recent systematic review evaluating ginseng formu-
lae for stable COPD showed promising evidence of lung
function and QoL improvements. Included studies had
certain methodological weaknesses [17] however these
encouraging results prompt the need for rigorously
designed randomised controlled trials (RCTs) of high
methodological quality.
Objective
The objective of this study is to evaluate the therapeu-
tic value and safety profile of a standardised root
extract of Panax ginseng C.A Meyer (ginseng) for
symptomatic relief, with a focus on QoL improvement
in individuals with moderate (GOLD Stage II) COPD
(FEV1/FVC < 0.7 and FEV1 50% - 80% predicted). To
fulfil the objective, answers to the following questions
will be addressed 1) Does a standardised extract of
ginseng produce beneficial effects/symptomatic relief
in subjects with moderate COPD, in terms of improved
QoL and/or improved respiratory function? 2) Does
standardised ginseng extract reduce the use of conven-
tional symptom-relief medication in subjects with
moderate COPD? 3) With six months treatment and
six months follow-up, what are the time courses of
onset and persistence of any beneficial effects of the
ginseng extract in subjects with moderate COPD? 4)
What adverse events does the ginseng extract produce
in subjects with moderate COPD?
Methods
Design
This study is a randomised, multi-centre, double-blind,
placebo-controlled, two-armed parallel clinical trial,
comparing a standardised ginseng extract to placebo.
The design of the study will integrate rigorous, contem-
porary clinical research methodology in accord with
principles set out in the Declaration of Helsinki and the
Good Clinical Practice guidelines with the theory that
guides the appropriate use of traditional Chinese medi-
cine in clinical practice. Reporting will be guided by the
CONSORT statement [18,19], including relevant inter-
vention extensions relating to herbal medicines [20].
Two hospitals in Melbourne, Australia will randomly
assign 168 patients with moderate COPD at a ratio of
1:1 into the ginseng group or matching placebo. Con-
senting eligible participants will be enrolled for 52
weeks and will be required to attend 6 visits in total.
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The trial is designed in three phases, 4 weeks run-in; to
ensure participants are clinically stable with respect to
their COPD, 24 weeks treatment; with either ginseng or
placebo capsules, and 24 weeks follow-up (Figure 1).
Study Duration
Ongoing recruitment will occur for a maximum period
of 21 months (October 2010 and June 2012) or until a
sample of 168 individuals are randomised.
Subjects
168 participants will be recruited through local advertis-
ing and doctor referrals from hospital outpatients and
general practice clinics. Interested participants can tele-
phone or email the trial co-ordinators at the corre-
sponding sites for further information. Participant
information and consent forms will be sent to interested
individuals to read over prior to scheduling their first
visit.
Inclusion criteria for participation in the trial
1) males and females aged 40 to 80 years inclusive; 2)
ex-smokers (ceased smoking at least three months prior
trial entry), and agree to refrain from smoking through-
out the trial; 3) satisfy the COPD diagnostic criteria for
moderate (stage II) defined by GOLD as post-broncho-
dilator spirometry, FEV1/FVC < 0.7 and FEV1 50% -
80% predicted; 4) are clinically stable, that is, did not
experience an acute infective exacerbation of COPD
from at least 4 weeks prior to trial entry; 5) meet the
Chinese medicine diagnostic criteria for Lung Qi defi-
ciency or Lung and Spleen Qi deficiency; and 6) give
written informed consent to participate.
Exclusion criteria
1) current smokers; 2) individuals with a diagnosis of
alpha1-antitrypsin deficiency; 3) a history of asthma or
chronic systemic infections or inflammatory conditions
in the last three months; 4) pregnancy, breast-feeding
or women intending to become pregnant during the
course of the study; 5) serious illnesses such as heart,
liver or kidney diseases; 6) those who are unable to
adequately perform spirometry tests; 7) those taking
long-term immunosuppressive agents or immunosti-
mulants; 8) those who have an allergic history to gin-
seng products; 9) those currently using a ginseng-
containing product or have used a ginseng product
within the last three months; 10) those who are cur-
rent users of anticoagulants, anti-hyperglycaemics or
monoamine oxidase inhibitor anti-depressants; and 11)
those who have undertaken pulmonary rehabilitation
within three months of the commencement of the
study, or intend to enter pulmonary rehabilitation dur-
ing the study.
Preliminary screening for eligibility will be undertaken
at Visit 1 and during the 4-week run-in period. After this
period if suitability continues, participants will be ran-
domly assigned to one of the two treatment groups, gin-
seng or matching placebo. Continued suitability requires
that they be clinically stable and not have experienced an
acute infective exacerbation of COPD during the run-in
period and that post-bronchodilator spirometry values
stay within the moderate (Stage II) range. Individuals
who do not meet the preliminary criteria will not be ran-
domised and their participation in the trial will be dis-
continued. Participants’ self-reported respiratory
symptoms, smoking status, current medications and
other medical conditions will be documented at baseline
and throughout.
As well as a conventional diagnosis of COPD per-
formed by a physician, participants must also meet the
appropriate Chinese medicine syndrome classifications
of Lung Qi deficiency or Lung and Spleen Qi deficiency.
A registered Chinese medicine practitioner will perform
this diagnosis and only those with either of the two syn-
dromes will be accepted into the study.
Ethics
This study has been approved by the relevant local
human research ethics committees (HRECs) of the par-
ticipating centres. Any amendments to the study proto-
col will be submitted to the HRECs for approval. HREC
reference numbers: Austin Health HREC/10/Austin/8
(H2010/03892), Eastern Health E90/0910 and RMIT
University E31/10.
Baseline / Preliminary eligibility 
Beginning of Run-In 
Visit 1 / Week 0 
Recruitment 
Randomisation / Beginning of treatment 
n = 168 
Visit 2 / Week 4 
Placebo 
n= 84 
Ginseng 
n = 84 
Mid-Treatment  
Visit 3 / Week 16 
End of treatment / Beginning of 
Follow-up 
Visit 4 / Week 28 
Completion of Trial 
Visit 6 / Week 52 
Analysis 
Mid-Follow-Up  
Visit 5 / Week 40 
Excluded 
(Eligibility criteria 
not met) 
Figure 1 Participation Flow Chart.
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Clinical trial notification has been filed with the Ther-
apeutic Goods Administration (TGA) Australia (CTN
numbers 2010/0449 for Austin Health and 2010/0419
for Eastern Health).
Randomisation
All eligible subjects will be randomised using two different
sizes of block randomisation sequences generated by com-
puter and stratified by site. Treatment allocation numbers
will be entered into individually sealed opaque envelopes
and provided to each site. At the time of randomisation
participants will draw an envelope. Each envelope contains
a number that is concealed to the treatment allocation.
Randomisation sequence and allocation will be concealed
to all study subjects, research staff, investigators and phar-
macists until completion of the study. The allocation list
will be protected by password access files and held by a
non-investigator independent. In the event of an emer-
gency medical situation the individual’s randomisation
code and group allocation could be identified.
Sample size
The sample size calculation is based on the effect size on
QoL changes in COPD subjects, in a RCT of one of the
most commonly used long-acting beta2-adrenoceptor
agonists (salmeterol) [21]. In the study, the mean score
change on the St Georges Respiratory Questionnaire
(SGRQ) was significantly higher (p < 0.05) in the treat-
ment group (-6.8 ± 13.2) than in the placebo group (-1.4
± 11.7) [21]. For the proposed study, to achieve a similar
difference between the ginseng extract and placebo treat-
ment groups with an 80% power and a two-tailed signifi-
cance level of 5%, it is estimated that a sample size of 84
subjects per group will be required, that is, 168 in total.
Intention-to-treat analysis will be applied to minimise
bias due to drop-outs.
Treatment
A standardised Panax ginseng C.A Meyer (Araliaceae;
Asian ginseng or Renshen) root extract will be used as
treatment. The ginseng and matching placebo (i.e. identi-
cal appearance, taste and odour) will be dispensed as
100 mg gel-filled soft capsules for oral intake twice daily,
for a total of 24 weeks. The standardised ginseng extract
and matching lactose-based placebo will be manufactured
in accordance with good manufacturing practice (GMP)
by Ginsana SA, Switzerland. The ginseng extract will be
standardised to contain 4% ginsenosides. Routine quality
control checks will be undertaken on the packaging and
contents of the batch to ensure stability and quality with
handling and storage also following GMP procedures. The
dosage of ginseng was determined by referencing previous
clinical trials for the same indication [22,23], and by
recommendations from the manufacturer. This product is
listed for use as an herbal medicine with the TGA Austra-
lia (ARTG 14987).
Throughout the trial, participants will be supplied
with symptomatic relief medication, a short acting
beta2-agonist Salbutamol, to be used on an as needed
basis. To monitor medication compliance, participants
will be required to document such use in a take home
diary. Participants will be asked to return any capsules
they have neglected to take so that these can be checked
against the diary entries.
Participants will be advised not to take certain COPD
medications throughout the trial. Such as; short acting
anti-cholinergics, long acting beta2-agonists, theophyl-
line, inhaled corticosteroids (ICS) and combination ICS/
beta2-agonists. ICS are recommended for more advanced
COPD sufferers and those with repeated exacerbations
[1]. The use of a long acting anti-cholinergics will be
allowed.
If exacerbations occur, management will be decided by
the patients’ own physician/healthcare provider and all
relevant details including medications will be recorded
by the research investigators as secondary outcomes.
The trial defines exacerbations as at least a 2-day persis-
tence of at least two major symptoms, such as worsen-
ing dyspnoea and an increase in sputum purulence,
volume, or both, or of any single major symptom plus
more than one minor symptom (upper airway infection,
unexplained fever, increased wheezing) [24].
Outcomes
The primary outcome measures will be QoL improvement
assessed by using three validated and self-administered
questionnaires.
• St Georges Respiratory Questionnaire (SGRQ)
• Short Form Health Survey (SF-36); and
• COPD Assessment Test (CAT)
Participants will complete the three questionnaires at
each visit, 6 times in total (Week 0, 4, 16, 28, 40 and
52). (Table 1)
Secondary outcome measures include efficacy and
safety components.
Lung function using spirometry indices of FEV1 and
FEV1/FVC ratio.
Use of relief medication short-acting bronchodilator
(beta2-agonist Salbutamol)
Frequency, nature and severity of exacerbations
Emergency department presentations and medical
practitioner visits
Full blood examination and blood biochemistry for
liver and renal function
Adverse event reporting
Spirometry at each site will be conducted using Spir-
oUSB™ (CareFusion) and Spida5® software. Routine
calibration and standard operating procedures will be
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uniformly undertaken at each site. Participants will be
asked to perform spirometry at each visit, 6 times in
total (Week 0, 4, 16, 28, 40 and 52). Participants will be
advised not to use respiratory medications for several
hours prior to their spirometry testing. Two sets of mea-
surements will be taken at each visit, pre-bronchodilator
and post-bronchodilator (post 400 μg of inhaled
Salbutamol).
Any adverse events will be listed in the trial record
and followed-up to completion by the trial co-ordinators
and respiratory physicians. Adverse event details will be
scored using a six-point scale, 0 = none, 1 = minimal, 2
= mild, 3 = moderate, 4 = severe, and 5 = extremely
severe. Participants will be able to report adverse events
anytime throughout the trial and will receive advice
accordingly. Serious adverse events will be reported to
the reviewing HREC and site HRECs within the time-
frame specified by the lead HREC.
Throughout the study period (52 weeks) trial coordi-
nators will contact the participant’s usual treating doc-
tor to record relevant data on presentations and
exacerbations.
To assist with outcome documentation and medica-
tion compliance, participants will be given a participant
diary to complete on a daily basis for the duration of
the trial. They will be asked to record trial medication
and relief medication usage as well as any new medica-
tions they commence during the trial.
Participants may withdraw from the study for any rea-
son at any time without repercussion. They will only be
withdrawn by investigators if it is deemed medically
unsafe for them to continue. Dropouts will not be
replaced.
Statistical analysis
The trial data will be analysed by an independent biostatis-
tician who will be blinded to the subject allocation. Pri-
mary outcome measures SGRQ, SF-36 and CAT scores of
participants in the treatment and placebo groups will be
assessed at baseline, start of treatment (4 weeks) mid-
treatment (16 weeks), end of treatment (28 weeks), mid
follow-up (40 weeks) and at the end of follow-up (52
weeks). A suitable statistical package such as SAS will be
used to analyse the data. An intention-to-treat analysis will
be applied using the Last Observation Carried Forward
(LOCF) method. Analysis of covariance with baseline as
covariate will be used to assess differences in treatment
outcomes between the two groups at each of these time
points. To correct for inflated risk of Type 1 error, multi-
ple comparison procedures suggested by Ludbrook et al
will be used [25,26]. The use of relief medication during
the trial will be investigated for its effect on the outcome
measures by using it as a covariate in the statistical analy-
sis. A Data Safety Monitoring Board has been established
to assess the progress of the trial, particularly safety
endpoints.
Discussion
This clinical trial will build on previous RCTs and sys-
tematic reviews on QoL improvements using ginseng
for COPD [17,22,23]. It has been designed by a multi-
disciplinary and international collaborative team and
will undertake a novel approached in integrating rigor-
ous, RCT methodologies and theory that guides appro-
priate use of Chinese medicine for translation into
clinical practice.
The trial will provide critical clinical data for effective-
ness and safety of Panax ginseng C.A Meyer root extract
for the improvement of QoL and pulmonary parameters
such as FEV1 and FVC ratio. Findings from this study may
lead to new therapeutic development for a range of
chronic inflammatory diseases, particularly chronic
respiratory diseases.
Publication and reporting date
Late 2012 or early 2013.
List of abbreviations
cAMP: cyclic adenosine monophosphate; CAT :COPD assessment test; COPD:
chronic obstructive pulmonary disease; CTN: clinical trial notification; FEV1:
forced expiratory volume in 1 second; FVC: forced vital capacity; GMP: good
manufacturing practice; GOLD: global initiative for chronic obstructive lung
disease; HREC: human research ethics committees; ICS: inhaled
corticosteroids; LOCF: last observation carried forward; NHMRC: National
Health and Medical Research Council; PDE4: phosphodiesterase 4; QoL:
Table 1 Measurements to be taken throughout the trial
Visit/Week 1/0 2/4 3/16 4/28 5/40 6/52
SGRQ ✓ ✓ ✓ ✓ ✓ ✓
SF-36 ✓ ✓ ✓ ✓ ✓ ✓
CAT ✓ ✓ ✓ ✓ ✓ ✓
Spirometry ✓ ✓ ✓ ✓ ✓ ✓
Full Blood Count ✓(Including alpha1 antitrypsin) ✓
Blood Biochemistry
KI & LR function
✓ ✓
CAT: COPD Assessment Test; KI: Kidney; LR: Liver; SF-36: Short Form Health Survey; SGRQ: St Georges Respiratory Questionnaire.
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quality of life; RCT: randomised controlled trial; RMIT: Royal Melbourne
Institute of Technology; SAS: statistical analysis software; SF-36: short form
health survey; SGRQ: St georges respiratory questionnaire; TGA: therapeutic
goods administration.
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